Physician profile
Ryan S Miller
NPI 1932262037
$5,191.21
in general payments reported to CMS, 2019-2025
19 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.65 · 2020: $27.96 · 2022: $150 · 2023: $4,264 · 2024: $259 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,511 · Food and Beverage: $1,249 · Travel and Lodging: $205 · Education: $23.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,511.25 |
| Food and Beverage | $1,248.87 |
| Travel and Lodging | $205.18 |
| Education | $23.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,161.10 | 2019-2025 | Norditropin, Sogroya |
| Sanofi-Aventis U.S. LLC | $243.18 | 2023-2025 | |
| Insulet Corporation | $125.00 | 2024 | Omnipod |
| Xeris Pharmaceuticals, INC. | $103.46 | 2022-2023 | Gvoke Hypopen |
| Abbvie INC. | $82.02 | 2023-2025 | |
| Kyowa Kirin, INC. | $56.48 | 2024-2025 | Crysvita |
| Dexcom, INC. | $54.10 | 2023-2025 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $53.92 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $49.73 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.45 | 2023-2024 | Gattex |
| Ascendis Pharma Endocrinology INC | $44.21 | 2025 | Skytrofa |
| Azurity Pharmaceuticals, INC. | $39.65 | 2023-2025 | Triptodur, Triptodur |
| Medtronic, INC. | $38.96 | 2022-2025 | Minimed 780g |
| Soleno Therapeutics, INC. | $24.83 | 2025 | Vykat Xr |
| Tandem Diabetes Care, INC. | $21.05 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $18.89 | 2025 | |
| Alexion Pharmaceuticals, INC. | $15.20 | 2023 | Strensiq |
| Calliditas Therapeutics US INC. | $14.98 | 2023 | Tarpeyo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.